Mecasermin rinfabate
Mecasermin Rinfabate
Mecasermin Rinfabate (pronunciation: meh-kah-ser-min rin-fah-bate) is a synthetic, recombinant DNA-derived, insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) complex. It is used in the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
Etymology
The name "Mecasermin Rinfabate" is derived from its chemical structure. "Mecasermin" is a combination of "mechanical" and "serum", referring to its synthetic nature and its role in the body's growth processes. "Rinfabate" is derived from "rin", meaning "to bind", and "fabate", a suffix often used in pharmaceutical naming to denote a drug's binding properties.
Usage
Mecasermin Rinfabate is administered through subcutaneous injection. It is typically used when other treatments for growth failure, such as growth hormone therapy, have proven ineffective.
Side Effects
Potential side effects of Mecasermin Rinfabate include hypoglycemia, lipohypertrophy, tonsillar hypertrophy, and serious allergic reactions.
Related Terms
- Insulin-like Growth Factor-1 (IGF-1)
- Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
- Growth Hormone Therapy
- Hypoglycemia
- Lipohypertrophy
- Tonsillar Hypertrophy
External links
- Medical encyclopedia article on Mecasermin rinfabate
- Wikipedia's article - Mecasermin rinfabate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski